Background: The non-interventional study CONIFER was designed to assess the safety and clinical practicability of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome (MDS) patients. Methods: Patients included in the study were diagnosed with MDS and received at least 1 treatment with deferasirox. The observation period covered the time from the initial visit until the last follow-up. Results: The data of 99 patients with MDS scored mainly as International Prognostic Scoring System (IPSS) low and intermediate 1 were evaluated. The mean age of the participants was 75 years and 58% of the patients were male. Iron overload was assessed by serum ferritin level (mean baseline serum ferritin 2,080 ± 1,244 µg/l). Patients were treated for a mean duration of 16 months (mean daily dose at baseline 11.8 ± 7.0 mg/kg). Stratification of serum ferritin levels by deferasirox dose showed a reduction at the higher but no reduction at the lower dose (< 15 mg/kg vs. ≥ 15 mg/kg and < 20 mg/kg vs. ≥ 20 mg/kg). The majority of patients (81%) were affected by at least 1 adverse event, with decreased renal creatinine clearance being the most frequent. Conclusion: Higher doses (≥ 15 mg/kg) of deferasirox effectively and safely reduced serum ferritin levels in MDS patients with transfusional iron overload.

Keywords:
Hematology, Oncology, Iron overload, Myelodysplastic syndrome, Deferasirox, Chelation therapy, Ferritin, Prospective study
1.
Oscier DG: ABC of clinical haematology. The myelodysplastic syndromes. BMJ 1997;314:883-886
2.
Scott BL, Deeg HJ: Myelodysplastic syndromes. Annu Rev Med 2010;61:345-358.
3.
Brissot P, Ropert M, Le Lan C, Loréal O: Non-transferrin bound iron: A key role in iron overload and iron toxicity. Biochim Biophys Acta 2012;1820:403-410.
4.
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P: LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-287.
5.
Jensen PD: Evaluation of iron overload. Br J Haematol 2004;124:697-711.
6.
Malcovati L, Porta MG, Pascutto C, et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
7.
Malcovati L: Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007;31 (Suppl 3):S2-6.
8.
Fenaux P, Haase D, Sanz GF, et al.: Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii57-69.
9.
Gattermann N, Jarisch A, Schlag R, et al.: Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: Results from the observational studies eXtend and eXjange. Eur J Haematol 2012;88:260-268.
10.
Cappellini MD, Cohen A, Piga A, et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462.
11.
Metzgeroth G, Dinter D, Schultheis B, et al.: Deferasirox in MDS patients with transfusion-caused iron overload - a phase-II study. Ann Hematol 2009;88:301-310.
12.
Greenberg PL, Koller CA, Cabantchik ZI, et al.: Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010;34:1560-1565.
13.
Gattermann N, Finelli C, Porta MD, et al.: Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010;34:1143-1150.
14.
Steensma DP, Gattermann N: When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol 2013;26:431-444.
15.
Möller HJ: Effectiveness studies: Advantages and disadvantages. Dialogues Clin Neurosci 2011;13:199-207.
16.
Neukirchen J, Fox F, Kündgen A, et al.: Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res 2012;36:1067-1070.
17.
van Spronsen MF, Ossenkoppele GJ, Holman R, van de Loosdrecht AA: Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. Eur J Cancer 2014;50:3198-3205.
18.
Park MJ, Kim HJ, Kim SH, et al.: Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol 2008;81:364-373.
19.
Olivieri NF, Nathan DG, MacMillan JH, et al.: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578.
20.
Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
21.
Breccia M, Alimena G: Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol 2013;92:863-870.
22.
Nolte F, Angelucci E, Beris P, et al.: Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res 2011;35:1131-1135.
23.
Vichinsky E: Clinical application of deferasirox: Practical patient management. Am J Hematol 2008;83:398-402.
24.
Adams RLC, Bird RJ: Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: A perspective review. Ther Adv Hematol 2013;4:93-102.
25.
Xia S, Zhang W, Huang L, Jiang H: Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: A meta-analysis of 16 randomized controlled trials. PLoS One 2013;8:e82662.
26.
McLeod C, Fleeman N, Kirkham J, et al.: Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: A systematic review and economic evaluation. Health Technol Assess 2009;13:III-IV, IX-XI, 1-121.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.